BACKGROUND: Porphyria cutanea tarda (PCT) occurs in sporadic (sPCT) and familial (fPCT) forms, which are generally clinically indistinguishable and have traditionally been differentiated by erythrocyte uroporphyrinogen decarboxylase (UROD, EC 4.1.1.37) activity. We used UROD gene sequencing as the reference standard in assessing the diagnostic accuracy of UROD activity, evaluating the mutation spectrum of the UROD gene, determining the frequency and disease attributes of PCT and its subtypes in Norway, and developing diagnostic models that use clinical and laboratory characteristics for differentiating fPCT and sPCT.
METHODS: All consecutive patients with PCT diagnosed within a 6-year period were used for incidence calculations. UROD activity analysis, UROD gene sequencing, analysis of hemochromatosis mutations, and registration of clinical and laboratory data were carried out for 253 patients.
RESULTS:
Fifty-three percent of the patients had diseaserelevant mutations, 74% of which were c.578GϾC or c.636ϩ1GϾC. The UROD activity at the optimal cutoff had a likelihood ratio (LR) of 9.2 for fPCT, whereas a positive family history had an LR of 19. A logistic regression model indicated that low UROD activity, a high uroporphyrin-heptaporphyrin ratio, a young age at diagnosis, male sex, and low alcohol consumption were predictors of fPCT. The incidence of PCT was 1 in 100 000.
CONCLUSIONS:
Two commonly occurring mutations are responsible for the high frequency of fPCT in Norway. UROD activity has a high diagnostic accuracy for differentiating the 2 PCT types, and a model that takes into account both clinical information and laboratory test results can be used to predict fPCT.
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Porphyria cutanea tarda (PCT) 5 is a disorder of porphyrin metabolism with associated skin photosensitivity that usually presents with vesiculobullous eruptions on the hands and face, and signs of liver damage. The disease is caused by a deficiency in uroporphyrinogen decarboxylase (UROD), the fifth enzyme in the heme synthesis pathway, and can be classified into several types, familial PCT (fPCT) and sporadic PCT (sPCT) being the most common. fPCT, an autosomal dominant disorder of low penetrance characterized by low UROD activity in all cells, constitutes about 25% of the cases in most populations (1) (2) (3) (4) (5) (6) (7) . The level of UROD activity in erythrocytes has traditionally been used to distinguish between fPCT and sPCT, because sPCT shows reduced UROD activity only in the liver. Both forms are considered clinically indistinguishable and are precipitated by the same factors: iron overload, infection by hepatitis C virus, and the use of estrogens and alcohol (8, 9 ) . The increasing public interest in hereditary diseases and genetic testing is likely to make differentiation between sPCT and fPCT increasingly important and consequently produce a greater demand for DNA analysis. In our experience, many PCT patients want to know whether they have a hereditary susceptibility for the disease, and their healthy family members want to be able to use this knowledge to consider precautions, particularly regarding the use of birth control pills in young women. The aims of this study were (a) to examine the diagnostic accuracy of UROD activity as a fPCT marker, with UROD 6 gene sequencing as the reference standard; (b) to estimate fPCT frequency and the spectrum of mutations responsible for fPCT in a large, ethnically homogeneous group of PCT patients; (c) to identify what other factors, including HFE (hemochromatosis) genotypes, characterize the 2 subtypes; (d) to use these factors and UROD activity to develop diagnostic models for differentiating sPCT and fPCT; and (e) to estimate the incidence of PCT in Norway.
Materials and Methods

PARTICIPANTS
We diagnosed PCT according to established criteria (8 ) and calculated disease incidence from all patients with PCT diagnosed at the Norwegian Porphyria Centre during 2000 -2005 and the first 5 months of 2006 (n ϭ 251). Material for DNA analysis was obtained from 196 of the patients and from 57 patients with previously diagnosed PCT who had control samples analyzed during the study period. These 253 patients were enrolled in the other parts of the study. Ostensibly healthy family members at risk for the disease (n ϭ 74) were tested during the study period and were included in parts of the study.
The UROD gene was sequenced in the 253 PCT patients for whom DNA samples were available. Seven of these patients possessed sequence variant c.1104*3GϾA, which has previously been reported as a likely diseasecausing mutation (10 ) . This variant coincided with well-established UROD mutations in 2 of these patients. The biochemical and clinical presentations of these 2 patients, however, were not compatible with hepatoerythropoietic porphyria. This variant was also seen in 3 of 200 healthy control individuals and was therefore categorized as a single-nucleotide polymorphism in our material (Table 1, II) . UROD sequence variants of undetermined significance were identified in 5 patients, and c.745CϾT coincided with c.876 -7_878dup10 in one of these patients (Table 1, III) . After excluding these 5 patients, we constituted the remaining 248 symptomatic index patients, hereafter denoted as "symptomatic PCT patients," as the main study individuals in this study. We analyzed HFE mutants encoding the C282Y and H63D variants in all patients and conducted analyses of the HFE mutant encoding the S65C variant in 243 patients and analyses of UROD activity and reticulocytes in 246 patients. For the 74 healthy family members at risk, we carried out genetic and biochemical testing primarily as for the symptomatic patients. We collected material for enzyme and DNA analyses simultaneously for each participant and carried out porphyrin analyses at the time of diagnosis for the symptomatic patients and at the time of genetic testing for the healthy family members at risk. A standardized questionnaire filled out by each patient's personal physician was used to gather information regarding time of disease onset, symptoms, provoking factors, liver-and iron-related biochemical variables at diagnosis, maltreatment, and family history. Questionnaires were returned for 73% of the patients. The study was approved by the Regional Ethics Committee of Western Norway.
BIOCHEMICAL METHODS
We removed the buffy coat of heparin-or EDTAanticoagulated blood and washed the erythrocytes in 0.15 mol/L NaCl. Erythrocyte UROD activity was measured essentially as previously described (11 ) . Reticulocytes were enumerated on the Cell-Dyn 4000 (Abbott Diagnostics) in a subsample of the washed blood sample. Analysis of urinary ␦-aminolevulinic acid and porphobilinogen was performed by the ALA/PBG Column Test (Bio-Rad Laboratories), followed by spectrophotometric measurements. Plasma samples were fluorometrically scanned as previously described (12 ) . Urine and fecal samples were both dissolved in 7 mol/L HCl and 0.1 mol/L phosphate buffer (pH 3.5) and extracted with 1 mL methanol on a solid-phase extraction column (Bond Elut C8; Varian). HPLC separation was performed on a BetaBasic 18 column (4.6 ϫ 150 mm, 5 m; Thermo Scientific) with a flow rate of 1.0 mL/ min and with mobile phases of 1 g/L trifluoroacetic acid in water and acetonitrile in a volume ratio of 70:30 (A) and acetonitrile (B). The gradient program was 0 -5 min (0%-50% B), 5-7 min (50%-100% B), 7.5-8.5 min (100%-0% B), and 8.5-13 min (hold at 0% B). Fluorometric detection was carried out with excitation at 403 nm and emission at 618 nm. Urinary creatinine was assayed on the Hitachi Modular P instrument (Roche Diagnostics). The total analytical CV (within-day and between-day) for a UROD activity of 1.8 U/L erythrocytes was 5.2% during the study period.
DNA SEQUENCING AND MUTATION DETECTION
DNA was purified from EDTA-treated blood with the BioRobot M48 workstation (Qiagen) according to the manufacturer's instructions. We used Oligo 6.3 software (Molecular Biology Insights) to design PCR primers for amplification of exons and flanking introns (at least 50 bp) for the UROD and HFE (exon 2 for S65C) genes. PCR and real-time PCR amplifications were performed with AmpliTaq Gold (Applied Biosystems) or Taq polymerase (Qiagen) according to the manufacturer's instructions. The PCR products were treated with shrimp alkaline phosphatase/exonuclease I (ExoSAP-IT, USB Corporation) and sequenced with the BigDye Terminator Cycle Sequencing Ready Reaction Kit, version 2.0 (Applied Biosystems) according to the manufacturer's instructions. The HFE mutants encoding the H63D and C262Y variants were determined by real-time allelic discrimination with the 7900HT Fast Real-Time PCR System (Applied Biosystems) ac-cording to the manufacturer's instructions. The presence of the S65C variant was determined by sequencing HFE exon 2 or via restriction enzyme analysis with HinfI (New England BioLabs). DNA samples from most patients with c.578GϾC were tested for up to 43 microsatellite marker loci surrounding the UROD locus on chromosome 1. Diagnostic samples from a few relatives of index patients were available for establishing definite haplotypes.
STATISTICAL ANALYSIS
Analyse-it® (Analyse-it Software) and Microsoft Excel® in Microsoft Office 2003 were used in ROC curve analysis to evaluate the diagnostic accuracy of UROD activity. General statistical analysis, group-comparison testing, table analysis, logistic regression, and correlation studies were carried out with SPSS® 15.0 for Windows (SPSS). Logistic regression analysis (with forward stepwise variable selection) was performed with the PCT disease type (sporadic/familial) as the dependent variable and the following sets of independent variables: (a) UROD activity alone (n ϭ 246); (b) UROD activity, HFE status with the genotypes in Table 2 and the wild-type/wild-type genotype as the reference category, sex (male, 0; female, 1), age at diagnosis, uroporphyrin-heptaporphyrin ratio (uroheptaporphyrin ratio), ferritin, ␥-glutamyltransferase, alanine aminotransferase, liver disease (absent, 0; present, 1), and high alcohol consumption (absent, 0; or present, 1), as scored by the patient's personal physician as a provoking factor for PCT (n ϭ 151); and (c) all variables in (b) except for UROD activity. Logistic regression analysis was also performed in the fPCT and sPCT subgroups with age at symptom onset (Ͻ50 years and Ն50 years) as the dependent variable and HFE status, sex, liver disease, high alcohol consumption, and estrogen use (absent, 0; present, 1) as the independent variables (n ϭ 166). CIs for indices of diagnostic accuracy were calculated by the Wilson score method (13 ) . All P values are the results of 2-tailed tests, and P values Ͻ0.05 are considered statistically significant.
Results
PCT was diagnosed in 251 consecutive patients with an even distribution over the study period. The Norwegian Porphyria Centre performs porphyria diagnostics for the entire population, and this result yields a minimum estimate for the incidence of symptomatic PCT in Norway of 1.0 per 100 000 inhabitants.
UROD AND HFE GENOTYPES
A disease-relevant sequence variant was identified in 131 (53%) of the 248 symptomatic PCT patients. UROD variants c.578GϾC and c.636ϩ1GϾC accounted for 30% and 44% of the fPCT cases, respectively (Table 1 ). There were no significant differences between sporadic and familial cases with regard to HFE status (Table 2) .
PATIENT CHARACTERISTICS
Dividing the symptomatic PCT patients into sporadic and familial cases according to the results of UROD gene sequencing revealed the differences between the 2 groups described in Table 3 . In addition, alcohol was more often a provoking factor among men than among women (43% vs 25%), and liver disease, primarily infection with hepatitis B and C viruses, was more frequent in males with sPCT than males with fPCT (29% vs 4%). Twenty-five percent of fPCT patients reported maltreatment (mainly antibiotics, cortisone, or a combination of both), compared with 13% of the sPCT patients. fPCT patients homozygous for the C282Y variant had a younger age of symptom onset (33 years) than either wild-type homozygotes (50 years) or all other HFE genotypes (49 years). A logistic regression analysis indicated that being male and the presence of liver disease predicted a younger age of disease onset in fPCT [odds ratio (OR), 2.9; 95% CI, 1.1-7.2] and sPCT (OR, 0.033; 95% CI, 0.004 -0.273), respectively.
DIAGNOSTICS
UROD activity was not correlated with the reticulocyte percentage (range, 0%-4%). Fig. 1 shows the distribution of UROD activities in fPCT and sPCT cases. Because the sample size was Ͼ200 (14 ), we used ROC curve analysis directly to identify the optimal cutoff of UROD activity. The cutoff of 1.3 U/L erythrocytes had a sensitivity of 96% (95% CI, 90%-99%), a specificity of 90% (95% CI, 82%-94%), a likelihood ratio (LR) of 9.2 (95% CI, 5.3-15.6), and positive and negative predictive values of 91% (95% CI, 84%-95%) and 95% (95% CI, 90%-98%), respectively (Fig. 2) . UROD activities and concentrations of urinary porphyrin a Analysis of S65C was not performed in 5 PCT patients, and results for these patients are not included. b Indicated are frequencies significantly different from those of healthy Norwegians (*P ϭ 0.02; **P Ͻ 0.001; ***P Ͻ 0.0001).
metabolites were similar in the 3 major sequencevariant groups (i.e., c.578GϾC, c.636ϩ1GϾC, and "others"). Use of an uroheptaporphyrin ratio Ͼ2.6 as a marker for fPCT had a sensitivity of 78% (95% CI, 70%-85%), a specificity of 51% (95% CI, 41%-60%), an LR of 1.6 (95% CI, 1.3-2.0), and positive and negative predictive values of 63% (95% CI, 55%-71%) and 68% (95% CI, 60%-75%), respectively (Fig. 2) . Having a positive family history of PCT had an LR of 19 (95% CI, 5-76) for diagnosing fPCT, and a negative or unknown family history had an LR of 0.7 (95% CI, 0.6 -0.8) ( ). All models gave essentially the same ORs for the different discriminators when they were applied to the patient subgroups with and without a positive family history of PCT.
PREDICTIVELY TESTED FAMILY MEMBERS
Forty-three of the 74 tested healthy family members at risk for the disease carried their family's mutation. Eight of these 43 individuals were in a subclinical disease state and fulfilled the biochemical criteria for PCT. All urinary metabolites with the exception of coproporphyrins were significantly lower in the subclinical Relatives with known PCT, % 2 (0-5)*** 32 (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) a The minimum number of patients with available data for clinical descriptors and liver variables was 159. Data are presented as the percentage (95% CI), the mean (95% CI), or as the median (10th percentile, 90th percentile), as indicated. For variables with nongaussian distributions, Student t-tests were performed after the data were transformed to natural logarithms. Indicated are statistically significant differences for sPCT vs fPCT (*P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.0001). b Upper reference limits are Ͻ240 g/L for females and Ͻ300 g/L for males. c ALT, alanine aminotransferase; ␥-GT, ␥-glutamyltransferase. patients than in the symptomatic PCT patients (median uroporphyrin concentration, 140 and 605 nmol/ mmol creatinine, respectively).
Discussion
PCT is the most prevalent porphyria in most populations and differs from the other hereditary porphyrias in that it also has a sporadic form. Our study is the first to report that the familial form may constitute more than half of the cases in a large national sample (Ͼ240 index patients). This frequency is significantly higher than frequencies reported for comparable populations (1, 3, 5 ). The largest of these studies (1 ) identified 19 fPCT cases in 84 patients, but because DNA analysis was performed only in patients with low UROD activity, the frequency of fPCT might have been underestimated by a few percent. The 2 other studies reported the familial form to constitute about 25% of cases when UROD gene analysis was performed in all patients [53 and 61 patients, respectively (3, 5 ) ], whereas 9 of 18 PCT patients in a Chilean study had familial disease (6 ) . Most (74%) of the fPCT cases in our study were caused by 2 frequently occurring mutations, c.578GϾC and c.636ϩ1GϾC. Gene-marker studies of c.578GϾC indicate that this variant is a founder mutation that originated in the northwestern part of southern Norway (data not shown). c.578GϾC was first reported in a patient in Utah (15 ) , and gene-marker analysis demonstrated that this patient was a descendent of the same ancestor. The sequence variant c.636ϩ1GϾC, which has been found in several unrelated patients, represents either an ancient mutational event or a hot spot for recurrent mutations (3, 15, 16 ) . All of our patients with the c.636ϩ1GϾC variant also carried the T allele in the single-nucleotide polymorphism c.636ϩ30GϾT (rs11211066), an observation compatible with a common origin of this mutation on a UROD haplotype with the rarer allele (T) in position c.636ϩ30. Founder mutations have not previously been reported in PCT, in contrast to, for example, W198X in acute intermittent porphyria (northern Sweden) (17 ) and the R59W variant in variegate porphyria (South Africa) (18 ) . We documented the incidence of PCT in Norway to be 1.0 per 100 000 inhabitants. Excluding patients with c.578GϾC and c.636ϩ1GϾC reduces the estimated incidence to 0.6 per 100 000. Few reports have documented the incidence of PCT, but an estimate of 0.2-0.5 per 100 000 population has been reported for the UK (9 ) .
A recent metaanalysis has shown that HFE genotypes encoding variants C282Y and/or H63D are associated with a 2-to 48-fold increased risk of PCT compared with the wild-type homozygote, with the C282Y/ C282Y conferring the highest risk (19 ) . Increased frequencies of C282Y homozygotes, C282Y/H63D compound heterozygotes, and H63D homozygotes were seen in our PCT patients, compared with the general Norwegian population, but no association was seen for S65C. The percentage of C282Y homozygotes was only 6.6%, which is low compared with reports of 15%-25% in PCT patients from Britain and Scandinavia, in which the general population frequencies of HFE genotypes are comparable to those of Norway (1, 20, 21 ) . The distributions of HFE genotypes in the sPCT and fPCT patient groups were not significantly different in our study, contrary to what has been found in studies in which the 2 disease forms were differentiated on the basis of UROD activity (2, 21 ) .
In general, PCT, particularly the sporadic type, has been considered to occur more frequently in men (9, 22 ) . In our study, however, 57% of the familial cases and 45% of the sporadic cases occurred in men (Table  3) . With the exception of the uroheptaporphyrin ratio, the 2 groups showed no significant differences with respect to the urinary excretion of porphyrins, in contrast with the finding in a smaller study of a higher concentration of total urinary porphyrins in fPCT patients (20 ) . C282Y homozygosity has been reported to be associated with an earlier onset of symptoms, in both the familial and sporadic disease types (1 ). Our logistic regression analysis, however, showed that only liver disease and sex predicted a younger age of disease onset, in the sporadic and the familial groups, respectively. The consequence of demonstrating the presence of an HFE mutation in a patient with PCT is in itself not apparent, because PCT patients generally exhibit biochemical signs of iron overload. One study found that chloroquine is not as effective in C282Y homozygotes as in the other HFE genotypes, but the treatment of choice will be venesection in most cases, irrespective of the results of HFE testing (23 ) .
UROD activity differentiates sporadic and familial cases of PCT quite well (LR of 9.2 at Ͻ1.3 U/L erythrocytes). In comparison, porphobilinogen deaminase activity has been shown to differentiate between patients with acute intermittent porphyria and their healthy relatives with an LR of 3.6 (24 ) . In several of the porphyrias, particularly erythropoietic protoporphyria, a small percentage of the patients with clear clinical and biochemical disease have no identifiable molecular defect (25 ) . Not finding a molecular defect in a "true" fPCT case in our study would have affected the diagnostic accuracy of UROD activity.
Having one or more family members with overt PCT is a strong predictor of the familial type. In our study group with a 53% prevalence of the familial type, such a family history would give a posttest probability of fPCT of 95% (Table 3) , and a prevalence of 20% would give a posttest probability of about 80%. Correspondingly, not having or "not knowing" about relatives with PCT would, in populations with fPCT prevalences of 53% and 20%, give posttest probabilities of 44% and 15%, respectively. Posttest probabilities of fPCT can also be calculated with various logistic regression models with different independent variables (Fig. 3) . With the use of UROD activity as the sole independent variable and a pretest probability of fPCT of 53%, a UROD result of Յ0.8 U/L erythrocytes will confirm fPCT, and a result of Ն1.6 U/L will exclude fPCT. Both give posttest probabilities of Ͼ90% (Fig. 3A) . Applying the same model in a patient with a positive family history, a UROD result of Յ1.3 U/L will produce only minor increases in the high posttest probability of fPCT. In a patient with a negative or unknown family history, however, a UROD result of Յ0.8 U/L increases the probability of fPCT from 44% to Ͼ90%. Extending the diagnostic model to include clinical and biochemical information, such as the patient being a young man at the time of diagnosis with low alcohol consumption and a high uroheptaporphyrin ratio, further increases the probability of fPCT (Fig. 3B) . When this diagnostic model (Table 1,  III) , the posttest probability of fPCT in the patient who carried both the disease-causing c.876 -7_878dup10 variant and c.745CϾT was 99%. The probability of fPCT in the 4 other patients ranged from 7% to 34%. If measurement of UROD activity is not available, a diagnostic model incorporating sex, age at diagnosis, uroheptaporphyrin ratio, ferritin, ␥-glutamyltransferase, alanine aminotransferase, and alcohol consumption can be used to differentiate sPCT and fPCT, but the model has low predictive power.
The clinical value of discriminating fPCT from sPCT is not clear. Although distinguishing the disease form at present does not appear to affect either the prognosis or the choice of treatment, our experience is that it is important for both patients and some of their family members to know whether the disease is hereditary. It is possible that the awareness of the hereditary aspect is higher in Norwegian patients, at least 20% of whom know of relatives with overt PCT. In addition, 20% of the healthy family members at risk in our study who had been demonstrated to carry their family's mutation had biochemically diagnosable PCT, indicating that the penetrance of fPCT is possibly higher than has heretofore been assumed. Future follow-up of these and similar patients is therefore important to further elucidate the importance of differentiating between fPCT and sPCT.
A diagnostic strategy for differentiating fPCT and sPCT can be derived from the information in this study, depending on what probability is deemed necessary for diagnosis, what clinical and laboratory data are known for the patient, what laboratory methods are available, and how they have been standardized. When a diagnostic strategy is to be implemented, it is important to have an estimate of the local prevalence of fPCT and to consider a possible spectrum bias.
